Clinical trial results for Tendoncel announced by Cell Therapy Ltd

30 Jun 2015

Cell Therapy Ltd has reported positive data from a Phase II trial of its topical regenerative medicine to repair severe tendon injury.  The company – based n Cardiff - tested Tendoncel in 34 patients with severe tendon injury (chronic grade 3 lateral epicondylitis) and measured change on two validated scales, namely DASH (Disabilities of the Arm, Shoulder and Hand) and PRTEE (Patient-Rated Tennis Elbow Evaluation).  Participants received 21 days of treatment with Tendoncel (a platelet lysate-derived combination of allogeneic growth factors in a cellulose gel) or with a placebo gel, after which Cell Therapy assessed their improvements against the two scales at the 6-week and three-month points. 

The company reported clinically relevant and statistically significant improvements in DASH (70%) and in PRTEE (74%).  Initial conclusions support potential applications of Tendoncel in a broad range of tendon injuries including shoulder and Achilles injuries.

Read more at  

Back to main news